Evidence map›Paper›PMID 34149901›Full record

ArticleOncology letters2021

IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer.

Thomas Crezee, Marika H Tesselaar, Martin Jaeger, Katrin Rabold, Willem E Corver, Hans Morreau, Adriana C H Van Engen-Van Grunsven, Jan W A Smit, Romana T Netea-Maier, Theo S Plantinga

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Thomas CrezeeDepartment of Pathology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Marika H TesselaarDepartment of Pathology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Martin JaegerRadboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Katrin RaboldDepartment of Internal Medicine, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Willem E CorverDepartment of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Hans MorreauDepartment of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Adriana C H Van Engen-Van GrunsvenDepartment of Pathology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Jan W A SmitDepartment of Internal Medicine, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Romana T Netea-MaierDepartment of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Theo S PlantingaDepartment of Pathology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Radboud University Nijmegen · NLRadboud University Medical Center · NLLeiden University Medical Center · NLRadboud Institute for Molecular Life Sciences · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differentiated thyroid cancer (DTC) is the most frequent endocrine tumor with a good prognosis after primary treatment in most cases. By contrast, 30-40% of patients with metastatic DTC are unresponsive to

Indexed as

DTCIGF2RAI refractoriness

Identifiers

PMID34149901
PMCPMC8200939
OpenAlexW3166348918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.